How is technology eliminating geography as a barrier to business operations and investment?
Technology has reduced the cost of operating across geographies to near zero for knowledge-based businesses, enabling global talent access, international customer acquisition, and cross-border capital formation that were structurally unavailable to most companies a decade ago. Businesses that internalize this shift are building TAM and margin advantages that geography-constrained competitors cannot replicate.
1. Technology has reduced the cost of operating across geographies to the point where location is no longer a primary constraint. 2. Companies that build global teams and customer bases from day one have structural advantages over those that expand sequentially. 3. Digital infrastructure enables emerging market talent to compete directly with traditional talent hubs at a fraction of the cost. 4. Investors must reassess market size assumptions for businesses that face no geographic ceiling on addressable market.
The United States healthcare system is one of the most expensive in the world, yet outcomes frequently lag behind peer nations. Two structural conditions define the current moment: a growing recognition that the existing model is unsustainable, and a rapid acceleration of technology-enabled alternatives that have the potential to fundamentally restructure delivery and economics.
The Cost Problem
U.S. healthcare spending reached $4.5 trillion in 2022, representing 17.3% of GDP. Despite this, life expectancy in the U.S. is lower than in most comparable developed economies. Administrative overhead, misaligned incentive structures, and fragmented care delivery account for a disproportionate share of spending relative to clinical output. The fee-for-service model, which rewards volume rather than outcomes, remains the dominant payment structure despite widespread acknowledgment of its dysfunction.
Technology as a Structural Lever
AI-enabled diagnostics, remote patient monitoring, and predictive analytics are not incremental improvements to the existing system. They represent structural alternatives that can identify disease earlier, reduce unnecessary procedures, and enable more efficient care pathways. The clinical and economic evidence for AI-assisted radiology, for example, shows meaningful improvement in diagnostic accuracy and throughput. Digital therapeutics approved for specific indications offer outcome-equivalent alternatives to drug therapy at lower cost.
The Capital Allocation Shift
Institutional capital is responding to this structural opportunity. Health tech and digital health companies raised over $29 billion in 2021 and have remained a significant allocation category despite the broader venture capital pullback. Strategic acquirers including hospital systems, payers, and pharmaceutical companies are actively building digital capabilities through M&A rather than internal development. The premium for defensible clinical data sets, FDA-cleared algorithms, and enrolled patient populations is high and rising.
The Investment Thesis
The most defensible investment positions in healthcare transformation are those that reduce cost while maintaining or improving outcomes, that have demonstrated clinical evidence and regulatory clearance, and that are positioned within existing reimbursement structures rather than dependent on system-level reform. Companies that can demonstrate reductions in total cost of care while generating measurable outcome improvements are the most attractive to both strategic acquirers and institutional capital in the current environment.
Technology is fundamentally dismantling geographic barriers to business operations, enabling companies to access talent, customers, and capital across borders at a scale and speed that was structurally impossible a decade ago. The companies that internalize this shift earliest are building durable competitive advantages.
When to speak with Chatsworth
You may benefit from an advisory conversation if your board is evaluating timing, valuation expectations, buyer universe quality, or diligence readiness. Chatsworth provides senior-led perspective on process design and execution risk independently of whether a mandate results.
Speak with the team →Marcus Magarian, Managing Director. M&A advisory, strategic advisory, cross-border transactions, and technology-sector advisory. chatsworthgroup.com/our-team/marcus-magarian
LinkedIn Profile →Strategic perspectives on M&A, capital formation, and cross-border transactions, delivered directly.
Subscribe